Bristol-Myers Squibb Company (BMY) Stock Price & Analysis
Market: NYSE • Sector: Healthcare • Industry: Drug Manufacturers - General
Bristol-Myers Squibb Company (BMY) Profile & Business Summary
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis. It also provides Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Abraxane, a protein-bound chemotherapy product; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; and Empliciti for the treatment of multiple myeloma. In addition, the company offers Zeposia to treat relapsing forms of multiple sclerosis; Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Inrebic, an oral kinase inhibitor indicated for the treatment of adult patients with myelofibrosis; and Onureg for the treatment of adult patients with AML. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in New York, New York.
Key Information
| Ticker | BMY |
|---|---|
| Exchange | NYSE |
| Official Site | https://www.bms.com |
Market Trend Overview for BMY
One model, two time views: what the market looks like right now, and where the larger trend is heading over time.
SRE (WhaleQuant Structural Regime Engine) SRE evaluates how price structure evolves across daily and weekly timeframes to define the prevailing market regime. Beyond identifying trends, consolidations, and exhaustion phases, it distinguishes between raw structural strength and deployable participation quality. The model dynamically adjusts for structural context and extension risk, assessing whether conditions are supportive, stretched, fragile, or structurally impaired. Its purpose is not to forecast precise price levels, but to determine whether risk deployment is aligned with underlying market structure.
Longer-Term Market Trend (Mid to Long Term)
Shows the bigger market trend, how strong it is, and where risks may start to build over the next few weeks or months. — Updated as of 2026-11-17 (ET)
As of 2026-11-17, BMY is moving sideways with low volatility. Over the longer term, the trend remains bullish.
BMY last closed at 61.35. The price is about 0.3 ATR above its recent average price (60.85), and the market is currently in a sideways market with low volatility. Price at 61.35 is moving between light support near 61.30 and moderate resistance near 62.25. Direction remains unclear. View Support & Resistance from Options
Price is moving in a tight range. This often leads to a stronger move once the range breaks, increasing one-sided risk.
Trend score: 40 out of 100. Overall alignment is unclear. The market is currently in a sideways phase with tightening price movement. The longer-term trend is still positive, but short-term signals are not yet confirming it.
There is no clear key risk boundary right now.
A systematic trend-activation signal was most recently triggered on 2026-10-22, reflecting a technical shift toward positive directional alignment.
[2026-11-10] Price moved quickly and looked strong, but participation was limited.
Recent bars show mixed price behavior without a clear shift in structural quality or efficiency.
Closing activity showed limited conviction and did not suggest strong overnight positioning.
The model stays neutral because the setup is not clear enough to justify a directional deployment.
The model does not deploy this setup because predictability is still too low, internal signals are not aligned strongly enough, and price is still close to a gamma transition zone. Predictability is 4%, agreement is 14%, and reversal risk is 24%.
NOTE: This next-day up/down probability forecast module is still being tested for accuracy. Please do not rely on it for investment decisions. The model does not account for black swan events or company-specific fundamental news, and its estimates are based solely on technical conditions, capital flow, and market sentiment. View forecast history
This estimate uses 1-minute price, volume, and VWAP data from the last 55 trading days, with turnover-based decay. The sample period is 2026-09-01 to 2026-11-17. The current price is 61.35, 0.16% below the estimated average cost of 61.45. An estimated 45.2% of recent positioning is below the current price, while 53.7% is above it. The peak-density price is 60.85. The largest concentrated cost region is 62.23 to 63.93 and contains 33.9% of the estimated distribution. The current price is within the 60.53 to 61.78 cost region. The nearest region below the current price is 59.68 to 59.73. The nearest region above the current price is 62.03 to 62.12.
Short Interest & Covering Risk for BMY
This analysis looks at overall short interest positioning, focusing on the broader setup rather than short-term noise.
Shows how likely a short squeeze may be under current market conditions.
Short Exposure Percentile
Short interest is relatively low, indicating limited pressure from short positions. (Historical percentile: 24%)
Structure Analysis
BMY Short positioning is starting to look crowded. Current days to cover is 4.2 trading days, meaning short positions would unwind somewhat slower than average. Short covering could add extra momentum to price moves. No meaningful structural fragility is currently detected (Fragility Score 0/100, DTC percentile 88%) and liquidity softening modestly (volume -16%). Positioning is historically elevated, although price and liquidity conditions do not yet confirm structural fragility.
Risk Summary
No clear bull trap characteristics detected. Recent price behavior remains broadly consistent with current positioning.This reading helps confirm that current price action remains structurally healthy and does not indicate elevated trap risk.
Why Price Reactions May Be Stronger?
Days-to-Cover is elevated versus its own history, but absolute short interest remains moderate. Adaptive thresholds applied to liquidity weakness, near-high detection, and compression sensitivity. As a result, similar news or market events could lead to price moves about 2× larger than usual.
Note:
Short interest data is reported every two weeks by
FINRA.
The most recent snapshot is
2026-10-30 (ET).
Because this data updates slowly, it is not intended to predict short-term price moves. Instead, it helps describe longer-term market structure and where pressure may be building if prices begin to move.